Tight junction protein 1 is regulated by transforming growth factor-β and contributes to cell motility in NSCLC cells

So Hee Lee; A Rome Paek; Kyungsil Yoon; Seok Hyun Kim; Soo Young Lee; Hye Jin You

doi:10.5483/bmbrep.2015.48.2.035

Tight junction protein 1 is regulated by transforming growth factor-β and contributes to cell motility in NSCLC cells

BMB Rep. 2015 Feb;48(2):115-20. doi: 10.5483/bmbrep.2015.48.2.035.

Authors

So Hee Lee¹, A Rome Paek², Kyungsil Yoon³, Seok Hyun Kim², Soo Young Lee⁴, Hye Jin You²

Affiliations

¹ Cancer Cell and Molecular Biology Branch, Div. of Cancer Biology, National Cancer Center, Goyang 410-769; Division of Molecular Life Sciences, Ewha Womans University, Seoul 120-750, Korea.
² Cancer Cell and Molecular Biology Branch, Div. of Cancer Biology, National Cancer Center, Goyang 410-769, Korea.
³ Lung Cancer Branch, Div. of Translational and Clinical Research I, National Cancer Center, Goyang 410-769, Korea.
⁴ Division of Molecular Life Sciences, Ewha Womans University, Seoul 120-750, Korea.

Abstract

Tight junction protein 1 (TJP1), a component of tight junction, has been reported to play a role in protein networks as an adaptor protein, and TJP1 expression is altered during tumor development. Here, we found that TJP1 expression was increased at the RNA and protein levels in TGF-β-stimulated lung cancer cells, A549. SB431542, a type-I TGF-β receptor inhibitor, as well as SB203580, a p38 kinase inhibitor, significantly abrogated the effect of TGF-β on TJP1 expression. Diphenyleneiodonium, an NADPH oxidase inhibitor, also attenuated TJP1 expression in response to TGF-β in lung cancer cells. When TJP1 expression was reduced by shRNA lentiviral particles in A549 cells (A549-sh TJP1), wound healing was much lower than in cells infected with control viral particles. Taken together, these data suggest that TGF-β enhances TJP1 expression, which may play a role beyond structural support in tight junctions during cancer development.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Benzamides / pharmacology
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / pathology
Cell Line, Tumor
Cell Movement / drug effects
Dioxoles / pharmacology
Gene Expression Regulation / drug effects*
Humans
Imidazoles / pharmacology
NADPH Oxidases / antagonists & inhibitors
NADPH Oxidases / metabolism
Onium Compounds / pharmacology
Pyridines / pharmacology
RNA Interference
RNA, Small Interfering / metabolism
Receptors, Transforming Growth Factor beta / antagonists & inhibitors
Receptors, Transforming Growth Factor beta / metabolism
Transforming Growth Factor beta / metabolism
Transforming Growth Factor beta / pharmacology*
Zonula Occludens-1 Protein / antagonists & inhibitors
Zonula Occludens-1 Protein / genetics
Zonula Occludens-1 Protein / metabolism*
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
p38 Mitogen-Activated Protein Kinases / metabolism

Substances

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
Benzamides
Dioxoles
Imidazoles
Onium Compounds
Pyridines
RNA, Small Interfering
Receptors, Transforming Growth Factor beta
Transforming Growth Factor beta
Zonula Occludens-1 Protein
diphenyleneiodonium
NADPH Oxidases
p38 Mitogen-Activated Protein Kinases
SB 203580